Reviewer's report

Title: Is Inhibition of Kinase Activity the Only Therapeutic Strategy for LRRK2-associated Parkinson's Disease?

Version: 1 Date: 12 November 2011

Reviewer: Jan O Aasly

Reviewer's report:

This is an excellent review; the authors are discussing the evidence underlying the idea that LRRK2’s kinase activity might be modified to protect against Parkinson’s disease. They are also focusing on other aspects of LRRK2 function that might equally be addressed therapeutically.

The manuscript does not seem to be updated when it comes to LRRK2 and other mutations.

They don’t discuss the EIF4G1 mutations in familial PD, recently published, which is involved in the regulation of factor eIF4E. They should also include the LRRK2 N1437H mutation, reported by Scandinavian and German groups.

They don’t mention LRRK2 and the risk for cancer. How would the use of kinase inhibitors change that risk?

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

‘I declare that I have no competing interests’